Pancreas Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
Select
IRB14-0660 A Randomized, Double-blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)
Select
IRB13-1503 A Phase 3, Multicenter, Open-Label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
Select
IRB13-0233 NCI 8993: A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma
Select
12-0159 A Pilot Study of neoadjuvant and adjuvant mFOLFIRINOX in localized, resectable pancreatic adenocarcinoma
Select
IRB14-0595 A genotype-guided dosing study of FOLFIRABRAX in previously untreated patients with advanced gastrointestinal malignancies
14492B Molecular Determinants of Malignancy in Pancreatic Cystic Neoplasms
Select
12-0033 A genotype-guided dosing study of mFOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
Select
IRB14-0873 A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy.
Select
16866B A Phase I Study of Stereotactic Body Radiation Therapy in Patients with Unresected Adenocarcinoma of the Pancreas or Ampulla
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team